Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05607953 · ClinicalTrials.gov registry record · Phase 1
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
A Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma, sponsored by TriSalus Life Sciences.
- Active
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05607953 is a Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma that is active but no longer recruiting, run by TriSalus Life Sciences. The registered enrollment target is 60 participants, roughly in line with the 64-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT05607953, a Phase 1 study of Locally Advanced Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by TriSalus Life Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is an open-label, phase 1/1b study of the pressure-enabled intrapancreatic infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with locally advanced pancreatic cancer.
Conditions Studied
Interventions
- DRUG SD-101
- BIOLOGICAL anti-PD-1
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05607953
The ClinicalTrials.gov registry entry for NCT05607953 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 64-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target. The listed sponsor is TriSalus Life Sciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which SD-101 is the first listed.
NCT05607953 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05607953 about?
NCT05607953 is a clinical study titled "Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma". This study is an open-label, phase 1/1b study of the pressure-enabled intrapancreatic infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with locally advanced pancreatic cancer.
What is the current status of trial NCT05607953?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-03-01. Estimated completion is 2027-10.
What conditions does trial NCT05607953 study?
This clinical trial studies the following conditions: Locally Advanced Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT05607953?
The interventions under investigation include: SD-101 (DRUG), anti-PD-1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05607953?
This trial is sponsored by TriSalus Life Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05607953 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
RECRUITING · Phase 1
-
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
RECRUITING · Phase 1
-
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
BATs Treatment for Pancreatic Cancer, Phase Ib/II
ACTIVE NOT RECRUITING · Phase 1
-
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.